Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 7.18
PACB's Cash to Debt is ranked higher than
67% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: 34.92 vs. PACB: 7.18 )
PACB' s 10-Year Cash to Debt Range
Min: 7.18   Max: No Debt
Current: 7.18

Equity to Asset 0.44
PACB's Equity to Asset is ranked higher than
58% of the 1122 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. PACB: 0.44 )
PACB' s 10-Year Equity to Asset Range
Min: -1.75   Max: 0.92
Current: 0.44

-1.75
0.92
F-Score: 4
Z-Score: -4.51
M-Score: -2.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -103.73
PACB's Operating margin (%) is ranked higher than
71% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. PACB: -103.73 )
PACB' s 10-Year Operating margin (%) Range
Min: -65237.04   Max: -103.73
Current: -103.73

-65237.04
-103.73
Net-margin (%) -109.19
PACB's Net-margin (%) is ranked higher than
70% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. PACB: -109.19 )
PACB' s 10-Year Net-margin (%) Range
Min: -64965.19   Max: -109.19
Current: -109.19

-64965.19
-109.19
ROE (%) -106.13
PACB's ROE (%) is ranked higher than
56% of the 1339 Companies
in the Global Biotechnology industry.

( Industry Median: -30.19 vs. PACB: -106.13 )
PACB' s 10-Year ROE (%) Range
Min: -272.85   Max: -46.42
Current: -106.13

-272.85
-46.42
ROA (%) -50.76
PACB's ROA (%) is ranked higher than
61% of the 1463 Companies
in the Global Biotechnology industry.

( Industry Median: -24.77 vs. PACB: -50.76 )
PACB' s 10-Year ROA (%) Range
Min: -81.89   Max: -41.75
Current: -50.76

-81.89
-41.75
ROC (Joel Greenblatt) (%) -801.22
PACB's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 1426 Companies
in the Global Biotechnology industry.

( Industry Median: -347.18 vs. PACB: -801.22 )
PACB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2466.26   Max: -529.13
Current: -801.22

-2466.26
-529.13
Revenue Growth (3Y)(%) 10.90
PACB's Revenue Growth (3Y)(%) is ranked higher than
83% of the 782 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. PACB: 10.90 )
PACB' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 38.3
Current: 10.9

0
38.3
EBITDA Growth (3Y)(%) -24.20
PACB's EBITDA Growth (3Y)(%) is ranked higher than
63% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. PACB: -24.20 )
PACB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -24.2
Current: -24.2

EPS Growth (3Y)(%) -22.60
PACB's EPS Growth (3Y)(%) is ranked higher than
65% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. PACB: -22.60 )
PACB' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -22.6
Current: -22.6

» PACB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

PACB Guru Trades in Q1 2014

Jim Simons 105,766 sh (New)
Steven Cohen 10,300 sh (New)
Lee Ainslie 6,459,784 sh (unchged)
Murray Stahl 12,000 sh (unchged)
» More
Q2 2014

PACB Guru Trades in Q2 2014

Lee Ainslie 6,459,784 sh (unchged)
Murray Stahl 12,000 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

PACB Guru Trades in Q3 2014

Lee Ainslie 6,459,784 sh (unchged)
Murray Stahl 12,000 sh (unchged)
» More
Q4 2014

PACB Guru Trades in Q4 2014

Jim Simons 137,972 sh (New)
Lee Ainslie 6,459,784 sh (unchged)
Murray Stahl 12,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PACB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.81
PACB's P/B is ranked higher than
59% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 6.95 vs. PACB: 7.81 )
PACB' s 10-Year P/B Range
Min: 0.52   Max: 10.44
Current: 7.81

0.52
10.44
P/S 7.07
PACB's P/S is ranked higher than
82% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 37.39 vs. PACB: 7.07 )
PACB' s 10-Year P/S Range
Min: 2   Max: 28.19
Current: 7.07

2
28.19
EV-to-EBIT -5.10
PACB's EV-to-EBIT is ranked higher than
53% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PACB: -5.10 )
PACB' s 10-Year EV-to-EBIT Range
Min: -7.9   Max: 0.5
Current: -5.1

-7.9
0.5
Current Ratio 3.74
PACB's Current Ratio is ranked higher than
70% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. PACB: 3.74 )
PACB' s 10-Year Current Ratio Range
Min: 3.74   Max: 22.74
Current: 3.74

3.74
22.74
Quick Ratio 3.38
PACB's Quick Ratio is ranked higher than
70% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. PACB: 3.38 )
PACB' s 10-Year Quick Ratio Range
Min: 3.38   Max: 22.74
Current: 3.38

3.38
22.74
Days Inventory 99.17
PACB's Days Inventory is ranked higher than
90% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PACB: 99.17 )
PACB' s 10-Year Days Inventory Range
Min: 104.94   Max: 196.1
Current: 99.17

104.94
196.1
Days Sales Outstanding 20.52
PACB's Days Sales Outstanding is ranked higher than
95% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. PACB: 20.52 )
PACB' s 10-Year Days Sales Outstanding Range
Min: 20.52   Max: 74.35
Current: 20.52

20.52
74.35

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.35
PACB's Price/Net Cash is ranked higher than
71% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 86.70 vs. PACB: 13.35 )
PACB' s 10-Year Price/Net Cash Range
Min: 1.02   Max: 17.42
Current: 13.35

1.02
17.42
Price/Net Current Asset Value 8.84
PACB's Price/Net Current Asset Value is ranked higher than
73% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 39.00 vs. PACB: 8.84 )
PACB' s 10-Year Price/Net Current Asset Value Range
Min: 0.89   Max: 11.53
Current: 8.84

0.89
11.53
Price/Tangible Book 7.81
PACB's Price/Tangible Book is ranked higher than
66% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. PACB: 7.81 )
PACB' s 10-Year Price/Tangible Book Range
Min: 0.8   Max: 7.36
Current: 7.81

0.8
7.36
Price/Median PS Value 0.91
PACB's Price/Median PS Value is ranked higher than
88% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. PACB: 0.91 )
PACB' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 1.5
Current: 0.91

0.48
1.5
Earnings Yield (Greenblatt) -19.60
PACB's Earnings Yield (Greenblatt) is ranked lower than
55% of the 1417 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. PACB: -19.60 )
PACB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 188.2   Max: 26942.4
Current: -19.6

188.2
26942.4

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:P09.Germany,
Pacific Biosciences of California Inc was incorporated in the State of Delaware in 2000. The Company develops, manufactures and markets an integrated platform for high resolution genetic analysis. It has developed a technology to study the synthesis, composition, structure, and regulation of DNA. Combining advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, it created a technology platform using its proprietary single molecule, real-time, or SMRT, technology. Its SMRT technology uses the natural processing power of enzymes, combined with specially designed reagents and detection systems, to record individual biochemical events. The ability to observe single molecule events in real time provides the scientific community with a tool for investigating basic biochemical processes such as DNA synthesis. Its SMRT technology has the potential to advance scientific understanding by providing a window into biological processes that has not previously been open. It has commercialized the PacBioRS II High Resolution Genetic Analyzer to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT) technology, its products enable scientists to increase their understanding of biological systems through targeted sequencing and insight into genetic variations. The Company's products include the SMRT Cell, Phospholinked nucleotides, the PacBio RS. Its competitors include Illumina Inc. and Thermo Fisher Scientific Inc. The names "Pacific Biosciences," "PacBio," "SMRT," "SMRTbell" and its logo are the trademarks of the Company. It is subject to federal, state, local and foreign laws, regulations and permits relating to environmental, health and safety matters.
» More Articles for PACB

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: CLR, CLMS, OPK, PACB, GAIN Dec 16 2013 
Weekly CEO Buys Highlight: OPK, PACB, CUBI, ARCP, RLYP Nov 25 2013 
Weekly CEO Buys Highlight: PHII, TUES, PACB, IPHI, WMC Dec 09 2012 
Weekly CEO Buys Highlight: PACB, AKS, EPIQ, GGS, TPGI Dec 02 2012 
Weekly CEO Buys Highlight: FFIN, STEC, MPO, PACB, TPGI Nov 25 2012 
Weekly CEO Buys Highlight: SUNS, PACB, GM, NPO, DGX Aug 11 2012 

More From Other Websites
Q1 2015 Pacific Biosciences of California Inc Earnings Release - After Market Close May 05 2015
BGI Adopts Single Molecule, Real-Time Sequencing from Pacific Biosciences May 04 2015
BGI Adopts Single Molecule, Real-Time Sequencing from Pacific Biosciences May 04 2015
Pacific Biosciences: What to Look for This Quarter - Analyst Blog May 01 2015
Nasdaq stocks posting largest percentage decreases Apr 29 2015
Pacific Biosciences Introduces New Solutions for Comprehensive and Efficient Targeted Sequencing and... Apr 27 2015
Pacific Biosciences Introduces New Solutions for Comprehensive and Efficient Targeted Sequencing and... Apr 27 2015
Pacific Biosciences of California, Inc. First Quarter 2015 Financial Results Call Apr 15 2015
Pacific Biosciences of California, Inc. First Quarter 2015 Financial Results Call Apr 15 2015
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Files SEC form 8-K, Change in Directors or Principal... Apr 13 2015
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Files SEC form 8-K, Entry into a Material Definitive... Apr 01 2015
Pacific Biosciences Announces Launch of Certified Service Provider Program for Single Molecule,... Mar 23 2015
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Financials Mar 19 2015
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Files SEC form 10-K, Annual Report Mar 12 2015
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Files SEC form 8-K/A, Change in Directors or Principal... Mar 10 2015
DNAnexus Enables Seamless Assembly of PacBio Data for J. Craig Venter Genome Mar 02 2015
Pacific Biosciences Enables Reference-Quality De Novo Human Genome Assemblies Mar 02 2015
Pacific Biosciences Enables Reference-Quality De Novo Human Genome Assemblies Mar 02 2015
10X Genomics Unwraps Its 'Toaster Oven' For Better DNA Sequencing Feb 25 2015
Five Things To Watch For At The Big Genomics Event Feb 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK